Exceptionally Promising Early Readouts for in vivo CAR-T Cells in 2026

Two near-identical lentiviral in vivo BCMA CAR‑T programs produced opposite 2026 outcomes: AstraZeneca/EsoBiotec’s ESO‑T01 showed efficacy but severe early Grade 3+ toxicities and an early halt, while Kelonia’s KLN‑1010 reported 100% ORR with mostly Grade 1-2 CRS at ASCO 2026. This analysis compares vectors, immune reactions, premedication and trial conduct, and explores implications for durability, commercialization and the future of in vivo CAR‑T in multiple myeloma.

Jun 14, 2026 7 min read

How CAR-T/TCR-T Therapy in Solid Tumors Is Shaping Up: Abstracts to Watch from ASCO 2026

At ASCO 2026, solid tumor CAR-T and TCR-T advances are showcased-from logic-gated safety (A2 Biotherapeutics’ Tmod) to GI-focused programs (CLDN18.2 satri‑cel, CDH17, dual CLDN18.2/NKG2D, intraperitoneal CEACAM5). The piece reviews glioblastoma, sarcoma PRAME TCR‑T, HCC GPC3, SCLC DLL3, and early engineering (NT‑175, MICA/B, CAR001), highlighting armoring, dual-targeting, gene editing, and the translational and commercial challenges ahead.

Apr 24, 2026 12 min read

Ten Preclinical Abstracts From AACR 2026 That Merit Attention

AACR 2026 roundup highlighting ten preclinical abstracts that signal meaningful advances in oncology drug discovery and immunotherapy. Features novel strategies for “undruggable” targets (c‑Myc degradation, HuR molecular glues), diverse KRAS approaches (inhibitors, degraders, molecular glues, oral macrocyclic peptide), ENA101 bispecific targeting an altORF antigen, delivery innovations (coacervate, nanoplasmids), DNA‑templated PROTACs, a macrophage PD‑1 endocytic checkpoint biomarker, and an engineered probiotic for metastatic PDAC.

Apr 11, 2026 8 min read

The 2025 State of Allogeneic Cell Therapies in Oncology

Discover the latest advancements in allogeneic cancer cell therapies and how they are revolutionizing the landscape of treatment efficacy and safety. Learn about the potential benefits of allogeneic cells over autologous CAR-T cells, advancements in clinical trials, and key players in the field. Explore the strategic shifts and promising data that hint at a future where allogeneic therapies could match or exceed the profile of autologous products. Stay informed about the evolving landscape of oncology cell therapies and the potential impact on patient outcomes.

Feb 22, 2025 3 min read

Catalysts and Insights from Gene Editing and Interfering Companies Presenting at JPM2025

Read about the latest updates and upcoming catalysts for Vertex Pharmaceuticals ($VRTX), Intellia Therapeutics ($NTLA), Sarepta Therapeutics ($SRPT), Alnylam Pharmaceuticals ($ALNY), Wave Life Sciences ($WVE), CRISPR Therapeutics ($CRSP), Prime Medicine ($PRME), Beam Therapeutics ($BEAM), Arcturus Therapeutics ($ARCT), Sana Biotechnology ($SANA), Editas Medicine ($EDIT), Verve Therapeutics ($VERV), and Allogene Therapeutics ($ALLO) in this comprehensive article by Sakis Paliouras, PhD. Stay informed on the groundbreaking advancements and potential milestones in the biotech and pharmaceutical industries.

Jan 18, 2025 18 min read

A Year In Review Part 2: The Most Impactful Solid Tumor Approvals of 2024

Discover the latest groundbreaking FDA approvals in the field of oncology with Amtagvi, Vyloy, Anktiva, Imdelltra, and Tecelra. Explore the efficacy, safety profiles, and market potential of these innovative treatments for melanoma, gastric cancer, bladder cancer, small-cell lung cancer, and synovial sarcoma. Stay informed on the advancements in tumor-infiltrating lymphocyte cell therapy, biomarker-driven agents, IL-15 agonists, bispecific antibodies, and TCR modified cell therapies reshaping the landscape of cancer treatments.

Dec 20, 2024 4 min read

A Year In Review Part 1: The Most Impactful Blood Cancer Approvals of 2024

Discover the latest advancements in cancer treatment with Revuforj, Blincyto, and Rytelo - three groundbreaking therapies approved by the FDA for different types of leukemia. From Menin inhibition to bispecific monoclonal antibodies and telomerase inhibition, these innovative drugs are revolutionizing the landscape of oncology. Learn about the clinical trials, approval processes, and expected market impact of these game-changing treatments. Stay informed with insights from Sakis Paliouras, PhD, and explore the potential of these medications in improving patient outcomes.

Dec 07, 2024 3 min read

A Deep Dive Into MAIA Biotechnology's NSCLC Program

Discover the latest on MAIA Biotechnology's Phase II NSCLC program, THIO-101, and its potential impact on immune checkpoint inhibitors. Unpack the survival data, safety profile, and comparisons to standard therapies like docetaxel + Cyramza. Gain insights on the FDA filing timeline and possible accelerated approval for THIO. Dive deep into the efficacy of THIO + Libtayo in the challenging NSCLC treatment landscape. Is this innovative therapy a game-changer for patients? Delve into the details with expert analysis by Sakis Paliouras, PhD.

Sep 18, 2024 5 min read

Tecelra's Approval for Synovial Sarcoma will Benefit Few Patients

Discover the groundbreaking approval of Tecelra, an innovative cell therapy for synovial sarcoma, marking a significant advancement in cancer treatment. Learn about its targeted approach and clinical trial results, as well as the challenges and potential limitations in its widespread use. Gain insights into the evolving landscape of sarcoma treatment and the potential impact of this new therapy. Explore the implications of this approval for patients, healthcare providers, and the pharmaceutical industry as a whole.

Sep 2, 2024 3 min read

Positive Results for Therapeutic Cancer Vaccines Pave Way for Commercialization

Discover the latest advancements in therapeutic cancer vaccines and their potential in revolutionizing cancer treatment. From dendritic cell vaccines to personalized mRNA vaccines, explore the promising frontier paving the way for improved survival outcomes. Uncover the results from recent studies and trials showcasing the efficacy and feasibility of these innovative cancer vaccines. With ongoing developments from leading biopharmaceutical companies, the future looks bright for the clinical application of therapeutic cancer vaccines in the near future.

Sep 1, 2024 3 min read

KRAS Inhibitors Will Struggle to Penetrate the First Line Treatment of NSCLC

Discover the latest advancements in KRAS inhibitors for oncology, including the FDA-approved G12C inhibitors Lumakras and Krazati for NSCLC. Dive into the challenges faced by these drugs in clinical trials, with a focus on efficacy and survival outcomes. Learn about ongoing trials for newly-diagnosed patients and the potential for next-generation KRAS inhibitors to revolutionize cancer treatment. Stay informed with key references from Amgen, BMS, and Eli Lilly. Stay ahead of the curve in the rapidly evolving landscape of oncology treatments with KRAS inhibitors.

Aug 31, 2024 2 min read

A Winner Emerges in the Battle for Multiple Myeloma CAR-Ts

Discover the latest advancements in CAR-T therapy for multiple myeloma and the battle between Abecma and Carvykti in the quest for more effective treatments. Learn about the FDA approvals, clinical trial results, and the implications for patient care as these groundbreaking therapies continue to evolve. Find out why Carvykti may be gaining the upper hand among physicians and how label expansions could shape the future of treatment for this challenging disease. Stay informed with insights from expert Sakis Paliouras, PhD.

Aug 30, 2024 3 min read